

CURRICULUM VITAE

PERSONAL DETAILS

Name	COGLIATI, VIOLA
Date of birth	11/05/1987
Residence	
E-mail	viola.cogliati@irccs-sangerardo.it
Phone	
Nationality	Italiana

PROFESSIONAL EXPERIENCE

- 02/2023 - ongoing
Oncologist at Phase 1 Research Centre
Clinical Post-Doctoral Fellowships 2023 –Fondazione Umberto Veronesi
Fondazione IRCCS San Gerardo dei Tintori, Monza
Hermione-13 trial; Clinical activity in breast oncology; Sub-investigator in Phase I, II, III clinical trials in Oncology
- 07/2021 - 01/2023
Oncologist at th Phase 1 Research Centre
San Gerardo Hospital-ASST Monza
Clinical activity in breast oncology; Sub-investigator in Phase I, II, III clinical trials in Oncology
- 11/2020 - 07/2021
Physician at Phase 1 Research Center, collaborative contract in emergency health care from Covid 19
San Gerardo Hospital-ASST Monza
Activities in support of Covid19 emergency and clinical activity in breast oncology; Sub-investigator in Phase I, II, III clinical trials in Oncology and Phase I, II clinical trials in anti-SARS-Cov2 vaccines.
- 01/2016 - 03/2021
Resident in Medical Oncology
University of Milan, San Gerardo Hospital-ASST Monza
- 01/2015 - 12/2016
Resident in Medical Oncology
University of Siena; Santa Maria alle Scotte, Hospital Siena
- 06/2014 - 12/2014
Substitute physician for continuity of care service
ASL Lecco
- 09/2013 - 09/2014
Physician , non-specialist, in Medical Oncology
Ospedale San Gerardo-ASST Monza
- 08/2013 - 01/2014
Physician in health care residence for disabled, Bresso (MI)

EDUCATION

- 17/03/2021
Speciality in Medical Oncology (70/70 cum laude)
With thesis entitled: "Retrospective, descriptive observational study of second lines of therapy after progression to CDK4/6 inhibitors in combination with hormone therapy "
University of Milan
- From 26/02/2013
Medical License number 01876, Lecco Registry
- 07/02/2013
National board for medical practice

University of Milano Bicocca, Italy

- 15/10/2012 M.D. Degree, School of Medicine (110/110 cum laude)
With Experimental Thesis titled: "Evaluation of cardiotoxicity in patients with advanced solid malignancies undergoing anti-VEGF drug therapy "
University of Milano Bicocca, Italy

2006 Graduation at High School-Liceo scientifico MG Agnesi, Merate (LC)

SKILLS

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

ENGLISH, B2 LEVEL;
FRENCH, B1 LEVEL

INFORMATICS

Good command of Microsoft Office tools (Word, Excel, Power Point)

GCP

Last GCP Training (With integrated modification of ICH E6) 26 January 2023

SCIENTIFIC PUBLICATIONS

Trabectedin (T) as second line treatment option for patients with epithelioid malignant pleural mesothelioma (MPM) in progression following pemetrexed/platin-derivates chemotherapy: ATREUS trial Cortinovis D, Hollander L, Carlucci L, Grosso F, Ceresoli, G, Pacchetti I, Zucali P, D'Incalci, M, Tiseo M, Legramandi L, Canova S, Ugo F, Abbate MI, Taverna G, **Cogliati V**, Bidoli, P. *Journal of Clinical Oncology* (2017). 35. 8513-8513.10.1200/JCO.2017.35.15_suppl.8513.

Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: from ALK positivity detection to treatment strategies after relapse. Cortinovis D, Canova S, Abbate MI, Colonese F, **Cogliati V** & Bidoli P. *Future Oncol.* 2018 Sep;14(22):2303-2317. doi: 10.2217/fon-2018-0066.

Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. Pilla L, Alberti A, Di Mauro P, Gemelli M, **Cogliati V**, Cazzaniga M, Bidoli P, Maccalli C. *Cancers*. (2020). 12. 3456. 10.3390/cancers12113456.

Metronomic Chemotherapy. Cazzaniga M, Cordini N, Capici S, **Cogliati V**, Riva F, Cerrito MG. (2021) *Cancers*. 13. 2236. 10.3390/cancers13092236.

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. Cazzaniga ME, Vallini I, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferrau F, Ferzi A, Baldelli A, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Sarti S, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Di Mauro P, **Cogliati V**, Capici S, Clivio L, Torri V; VICTOR Study Group. *Breast Cancer Res Treat.* 2021 Dec;190(3):415-424. doi: 10.1007/s10549-021-06375-5. Epub 2021 Sep 21.

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. **Cogliati V**, Capici S, Pepe FF, di Mauro P, Riva F, Cicchiello F, Maggioni C, Cordini N, Cerrito MG, Cazzaniga ME. *Life (Basel)*. 2022 Mar 5;12(3):378. doi: 10.3390/life12030378.

Exceptional disease control with neratinib monotherapy in HER2-positive advanced breast cancer: A case report. Pierluigi di Mauro, Serena Capici, **Viola Cogliati**, Francesca Fulvia Pepe, Claudia Maggioni, Francesca Riva, Federica Cicchiello, Marina Elena Cazzaniga. *Current Problems in Cancer Case Reports*, Volume 6, 2022, 100167, ISSN 2666-6219.

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target is Not Everything. Capici S, Ammoni LC, Meli N, **Cogliati V**, Pepe FF, Piazza F, Cazzaniga ME. *Cancers (Basel)*. 2022 Jul 31;14(15):3729. doi: 10.3390/cancers14153729

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows. Cazzaniga ME, Capici S, Cordini N, **Cogliati V**, Pepe FF, Riva F, Cerrito MG. *J Clin Med.* 2022 Aug 12;11(16):4710. doi: 10.3390/jcm11164710.

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study. Pepe FF, Cazzaniga ME, Baroni S, Riva F, Cicchiello F, Capici S, **Cogliati V**, Maggioni C, Cordini N, Cerrito MG, Malandrini S. *BMC Cancer.* 2022 Sep 6;22(1):956. doi:10.1186/s12885-022-10031-6.

Twist1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells. Cordini N, Mologni L, Piazza R, Tettamanti P, **Cogliati V**, Mauri M, Villa M, Malighetti F, Di Bella C, Jaconi M, Cerrito MG, Cavaletti G, Lavitrano M, Cazzaniga ME. *Int J Mol Sci.* 2023 Nov 14;24(22):16294. doi: 10.3390/ijms242216294. PMID: 38003483; PMCID: PMC10671583.

Abstract P6-01-42: BASELINE 18FDG-PET METABOLIC TUMOUR VOLUME (MTV) AS A POTENTIAL PREDICTIVE FACTOR OF RESPONSE TO METRONOMIC CHEMOTHERAPY (mCHT) IN HR+/HER2- METASTATIC BREAST CANCER (MBC) PATIENTS (pts). PRELIMINARY RESULTS OF THE METRO-PET STUDY. Meazza Prina Marco; Gotuzzo Irene; Cazzaniga Marina; Capici Serena; **Cogliati Viola**; Pepe Francesca; Cicchiello Federica; Riva Francesca; Cordini Nicoletta; Cerrito Maria Grazia; Turolla Elia; Landoni Claudio; Elisei Federica; Crivellaro Cinzia;

Virdone Leonardo; Monaco Lavinia; Guidi Alessandro; Guerra Luca. (2023). Cancer Research. 83. P6-01. 10.1158/1538-7445.SABCS22-P6-01-42.

Abstract P1-13-21: Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells . Cordani Nicoletta; Mogni Luca; Piazza Rocco; **Cogliati Viola**; Pepe Francesca; Capici Serena; Di Bella Camillo; Jaconi Marta; Cerrito Maria Grazia; Tettamanti Pietro; Cavaletti Guido; Lavitrano Marialuisa; Cazzaniga Marina. (2023).Cancer Research. 83. P1-13. 10.1158/1538-7445.SABCS22-P1-13-21.

417P New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/ human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study
Cogliati, V. Rossi, E. Turla, A. Ambroggi, M. Berardi, R Borella, F Coltelli, L Giorgi, U.F.F. Ferro, A. Garrone, O. Giordano, M. Landucci, E. Mazzotta, M Moretti, G. Palumbo, R Vici, P Zustovich, F. Riva, F Capici, S. Cazzaniga, M. (2023). Annals of Oncology. 34. S358. 10.1016/j.annonc.2023.09.594.

EDUCATIONAL ACTIVITIES

Participation in national and international congresses in the field of oncology

- 08/2011- 09/2011 Internship training in pediatric oncohematology and pediatric emergency room
Hopital Infantil "Manuel De Jesus Rivera, La Mascota" Managua, Nicaragua
Exchange Project – *University of Milano Bicocca*
- 02/2010-06/2010 Internship training in Oncology, Senology and Nuclear Medicine
Centre Regional d'Oncologie "Paul Strauss" Strasbourg, France
Erasmus Project; *Université de Starsbourg, France*

I hereby authorize the use of my personal details as per D.L. 196/03 and GDPR.

29 Jan 2024,

